drugset / Trial / NCT05838729
Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer
Phase 1/2
Recruiting
16 enrolled
Coordination Pharmaceuticals, Inc.
University of Illinois at Chicago · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, open-label, single arm, non-randomized study of RiMO-301 with hypofractionated radiation and a PD-1 Inhibitor in patients with unresectable, recurrent or metastatic head-neck cancer.
Timeline
- Start
- 2023-04-03
- Primary completion
- 2026-09
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Temozolomide | Small molecule | — | Other |
| Background | Nivolumab | Monoclonal antibody | — | Intravenous |
| Background | Pembrolizumab | Monoclonal antibody | — | Intravenous |